Follow
Joshua M. Staley
Joshua M. Staley
Senior Research Associate, The University of Kansas Cancer Center
Verified email at kumc.edu
Title
Cited by
Cited by
Year
Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I–III triple-negative breast cancer (NeoSTOP)
P Sharma, BF Kimler, A O'Dea, L Nye, YY Wang, R Yoder, JM Staley, ...
Clinical Cancer Research 27 (4), 975-982, 2021
632021
Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC)(NeoPACT).
P Sharma, SR Stecklein, R Yoder, JM Staley, K Schwensen, A O'Dea, ...
Journal of Clinical Oncology 40 (16_suppl), 513-513, 2022
452022
Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer
R Yoder, BF Kimler, JM Staley, K Schwensen, YY Wang, K Finke, A O’Dea, ...
npj Breast Cancer 8 (1), 1-7, 2022
232022
Making Sense of Pharmacovigilance and Drug Adverse Event Reporting: Comparative Similarity Association Analysis Using AI Machine Learning Algorithms in Dogs and Cats
X Xu, R Mazloom, A Goligerdian, J Staley, M Amini, G Wyckoff, J Riviere, ...
Topics in Companion Animal Medicine, 100366, 2019
192019
ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease
SR Stecklein, BF Kimler, R Yoder, K Schwensen, JM Staley, QJ Khan, ...
NPJ Breast Cancer 9 (1), 10, 2023
122023
Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC).
P Sharma, VG Abramson, A O'Dea, LE Nye, IA Mayer, GJ Crane, M Elia, ...
Journal of Clinical Oncology 39 (15_suppl), 1076-1076, 2021
82021
Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial
P Sharma, SR Stecklein, R Yoder, JM Staley, K Schwensen, A O’Dea, ...
JAMA oncology 10 (2), 227-235, 2024
52024
Novel Data Sharing Agreement to Accelerate Big Data Translational Research Projects in the One Health Sphere
J Staley, R Mazloom, P Lowe, CT Newsum, M Jaberi-Douraki, J Riviere, ...
Topics in Companion Animal Medicine 37 (December 2019), 100367, 2019
52019
Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis …
SR Stecklein, R Yoder, JM Staley, Z Schmitt, A O'Dea, LE Nye, M Elia, ...
Journal of Clinical Oncology 41 (16_suppl), 507-507, 2023
42023
Extinction of chromosomes due to specialization is a universal occurrence
J Wilson, JM Staley, GJ Wyckoff
Scientific Reports 10 (1), 2170, 2020
32020
Extracellular vesicle-derived non-coding RNAs to predict outcome in patients with triple-negative breast cancer (TNBC) with residual disease (RD).
SR Stecklein, D Koestler, NK Yellapu, R Yoder, BF Kimler, JM Staley, ...
Journal of Clinical Oncology 41 (16_suppl), 578-578, 2023
22023
Abstract PD11-07: PD11-07 Association of TNBC-DX scores with outcomes in triple-negative breast cancer (TNBC) treated with neoadjuvant pembrolizumab and chemotherapy: a …
P Sharma, SR Stecklein, R Yoder, JM Staley, R Salgado, L Paré, B Conte, ...
Cancer Research 83 (5_Supplement), PD11-07-PD11-07, 2023
22023
Abstract P2-01-05: Impact of post-treatment ctDNA and residual cancer burden (RCB) on outcomes in patients with triple-negative breast cancer (TNBC) and residual disease
P Sharma, SR Stecklein, BF Kimler, R Yoder, K Schwensen, JM Staley, ...
Cancer Research 82 (4_Supplement), P2-01-05-P2-01-05, 2022
2*2022
Tumor-infiltrating lymphocytes refine outcomes in triple-negative breast cancer treated with anthracycline-free neoadjuvant chemotherapy
M Martín, R Yoder, R Salgado, M del Monte-Millán, EL Alvarez, ...
Clinical Cancer Research, 2024
12024
Abstract PD1-06: Black patients with triple negative breast cancer (TNBC) have enriched stromal tumor infiltrating lymphocytes (sTILs) and receive preferential benefit from …
SR Stecklein, R Yoder, R Salgado, JM Staley, A O’Dea, L Nye, M Elia, ...
Cancer Research 83 (5_Supplement), PD1-06-PD1-06, 2023
12023
Abstract PS6-04: Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2 negative breast cancer
R Yoder, BF Kimler, JM Staley, K Schwensen, YY Wang, K Finke, A O'Dea, ...
Cancer Research 81 (4_Supplement), PS6-04-PS6-04, 2021
12021
Orphan noncoding RNA (oncRNA) liquid biopsy assay is prognostic for survival in patients with triple-negative breast cancer (TNBC) and residual disease
R Yoder, J Yen, M Karimzadeh, JM Staley, I Fernandez, AC Heinrich, ...
Cancer Research 84 (6_Supplement), 5215-5215, 2024
2024
Spatial organization of tumor-infiltrating lymphocytes (TILs) is prognostic for survival in triple negative breast cancer (TNBC)
SH Patel, G Corredor, R Yoder, C Barrera, M Castillo, L Bernabe, J Staley, ...
Cancer Research 83 (7_Supplement), 6623-6623, 2023
2023
A framework for determining orthologues gene-drug targets based upon function, evolutionary selection rate, and physiological location.
JM Staley, J Wilson, J Kawakami, J Rivere, GJ Wyckoff
Kansas State University, 2019
2019
The system can't perform the operation now. Try again later.
Articles 1–19